HOME >> BIOLOGY >> NEWS
UF Researchers Use Gene Therapy To Prevent Hypertension, Organ Damage

rt Association estimates as many as 50 million Americans 6 and older have high blood pressure, and 35 percent of them do not know it.

High blood pressure is particularly prevalent in blacks, heavy drinkers, women taking oral contraceptives, and those who are middle-aged, elderly or obese.

Though high blood pressure is easily detected and usually controllable with daily medication, doctors are unsure whether this treatment reverses other hypertension-induced changes in the body, such as heart and kidney damage.

In the UF study, researchers treated rats genetically predisposed to high blood pressure with antisense, a form of DNA in which the normal genetic code is reversed. The antisense is packaged within an inactivated, harmless virus called a retrovirus and injected into the bloodstream. The antisense interacts with the cell wall to reduce the potentially harmful effects of the angiotensin II hormone. High blood pressure and organ damage were prevented in all of the animals in which the treatment was successfully delivered.

"There are a number of pathophysiological changes associated with high blood pressure, and we chose to look at six," said Gelband, an assistant professor of physiology in the UF College of Medicine. "All six of these problems were prevented. We now plan to study whether gene therapy can reverse organ damage in adult animals with high blood pressure."

Gene therapy studies for high blood pressure have been under way at UF for a number of years. M. Ian Phillips, professor and College of Medicine physiology department chairman, previously has shown gene therapy can reduce high blood pressure in adult animals.

Jeffrey Martens, a graduate student in pharmacology and the current paper's lead author, said gene therapy may someday offer an alternative treatment for people genetically predisposed to high blood pressure.

"We have not identified the gene that causes high blood pr
'"/>

Contact: John Lester
JCLester@ufl.edu
352-392-0186
University of Florida
2-Mar-1998


Page: 1 2 3

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Researchers Use Gene Therapy Prevent Hypertension Organ Damage

(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: